Rhumbline Advisers Boosts Stake in Translate Bio Inc (NASDAQ:TBIO)

Rhumbline Advisers grew its stake in shares of Translate Bio Inc (NASDAQ:TBIO) by 207.4% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 31,712 shares of the company’s stock after buying an additional 21,397 shares during the period. Rhumbline Advisers’ holdings in Translate Bio were worth $323,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Barclays PLC grew its holdings in Translate Bio by 82.8% in the 4th quarter. Barclays PLC now owns 6,710 shares of the company’s stock worth $50,000 after acquiring an additional 3,039 shares during the last quarter. BNP Paribas Arbitrage SA bought a new stake in shares of Translate Bio during the 1st quarter valued at about $63,000. Two Sigma Investments LP bought a new stake in shares of Translate Bio during the 4th quarter valued at about $118,000. Teachers Advisors LLC bought a new stake in shares of Translate Bio during the 3rd quarter valued at about $126,000. Finally, Bailard Inc. bought a new stake in shares of Translate Bio during the 1st quarter valued at about $135,000. Hedge funds and other institutional investors own 57.90% of the company’s stock.

NASDAQ:TBIO opened at $10.10 on Thursday. Translate Bio Inc has a one year low of $4.81 and a one year high of $16.60. The company has a debt-to-equity ratio of 1.34, a quick ratio of 7.69 and a current ratio of 7.69. The stock has a market cap of $511.57 million and a P/E ratio of -2.77.

Translate Bio (NASDAQ:TBIO) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.04). The company had revenue of $1.47 million for the quarter. Research analysts anticipate that Translate Bio Inc will post -1.57 EPS for the current fiscal year.

TBIO has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of Translate Bio in a research note on Tuesday, April 9th. Zacks Investment Research raised shares of Translate Bio from a “sell” rating to a “hold” rating in a research note on Tuesday, May 21st. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $22.75.

ILLEGAL ACTIVITY WARNING: “Rhumbline Advisers Boosts Stake in Translate Bio Inc (NASDAQ:TBIO)” was first reported by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://dakotafinancialnews.com/2019/06/13/rhumbline-advisers-boosts-stake-in-translate-bio-inc-nasdaqtbio.html.

Translate Bio Profile

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

See Also: Bull Market

Want to see what other hedge funds are holding TBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Translate Bio Inc (NASDAQ:TBIO).

Institutional Ownership by Quarter for Translate Bio (NASDAQ:TBIO)

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.